Survival data for Bristol-Myers Squibb Co.'s Yervoy/Opdivo combination in the CheckMate 067 study in frontline melanoma reinforce the regimen's potency, but also revive a debate about whether the regimen should be reserved for select subsets of patients, with others getting enough benefit from Opdivo alone or other treatment options.
The combination of Yervoy (ipilimumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor, received accelerated approval from FDA in...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

